Integration of lateral flow and microarray technologies for multiplex immunoassay: application to the determination of drugs of abuse

Point-of-care diagnostic devices present a viable option for the rapid and sensitive detection and analysis of cancer markers. With the growing number of cancer cases being diagnosed worldwide and the increased number of fatalities due to late disease detection, biosensors can play an important role in the early diagnosis of cancer. Molecular profiles of patients are being increasingly studied using new molecular tools such as genomic and proteomic techniques. These methods combined with bioinformatics tools are generating new data which is being employed in the elucidation of new disease biomarkers. As with many disease conditions finding specific and sensitive markers that are associated with only one type of the disease can be difficult. In addition to this, the level of the biomarkers in biological fluids can vary depending on different disease conditions and stages. A number of molecular markers are therefore usually evaluated for cancer diagnosis and these can include proteins, peptides, over/under expression of gene markers and gene mutations. This review provides an overview of the biosensor technology available today, areas which are currently being developed and researched for cancer markers diagnosis-and a consideration of future prospects for the technology.

This article is an overview the state of the art and the recent developments in immunosensors. Homogeneous immunosensors, heterogeneous immunosensors, integrated immunosensors and biochip format immunosensors are presented, based on optical, electrochemical, magnetic or mechanical detection/transduction systems.